Investigational drug · Phase 2
OPT101
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Type I Diabetes.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "OPT101"
First trial start
2026
Apr 23, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "OPT101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Type I Diabetes
Approved drugs for the same conditions: Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "OPT101" as an intervention, largest first.
Op-T LLCIndustry
NCT06964087 · 72 participants (planned) · Start Apr 23, 2026 · Primary completion May 31, 2027
Drug: OPT101 · For: Type I Diabetes
Sites: Birmingham, Alabama; Walnut Creek, California; Aurora, Colorado · 5 sites in all
Op-T LLCIndustry
NCT06669403 · 26 participants (planned) · Start Mar 9, 2026 · Primary completion Mar 2027
Drug: OPT101 · For: Sepsis; Community Acquired Pneumonia (CAP)
Sites: Denver, Colorado; Valhalla, New York
- OPT101 in Type 1 Diabetes PatientsCompleted
Op-T LLCIndustry
NCT05428943 · 24 participants · Start Sep 27, 2022 · Primary completion Feb 21, 2024
Drug: OPT101 · For: Diabetes Mellitus, Type 1
Sites: Walnut Creek, California; Renton, Washington
- 1a/1b Study of OPT101 First in Human Study Assessing Safety and Tolerability of 15-mer Peptide.Completed
Op-T LLCIndustry
NCT04589403 · 14 participants · Start Feb 18, 2021 · Primary completion Sep 27, 2021
Drug: OPT101 · For: Healthy
Sites: Centennial, Colorado
Newest research
PubMed records naming it or its code names, newest first.
- Non-invasive near-infrared measurement of blood concentration in chest tube output: a proof-of-concept study.
Gonzalez J, Binns TC, Karam O · Biomed Phys Eng Express 2026
- Toward Mobile Neuroimaging: Design of a Multi-Modal EEG/fNIRS Instrument for Real-Time Use.
Barras M, Booth L, Bateson AD, et al. · Sensors (Basel) 2026
- A Brief Review of OPT101 Sensor Application in Near-Infrared Spectroscopy Instrumentation for Intensive Care Unit Clinics.
Li T, Zhong F, Pan B, et al. · Sensors (Basel) 2017
- [Study on spectral detection of green plant target].
Deng W, Zhao CJ, He XK, et al. · Guang Pu Xue Yu Guang Pu Fen Xi 2010
- [The design and improvement of photoelectric pulse sensor].
Zhang X, Zhou J · Zhongguo Yi Liao Qi Xie Za Zhi 2009
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.